Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21872497 | 0.94 | SLC18A2 (0.38) | SLC18A2CYP1A2CYP2D6HIF1AKMT2A | |
| SCHEMBL22113042 | 0.88 | SLC18A2 (0.44) | SLC18A2 | |
| SCHEMBL13115855 | 0.88 | SLC18A2 (0.31) | SLC18A2 | |
| SCHEMBL13634410 | 0.88 | SLC18A2 (0.31) | SLC18A2 | |
| SCHEMBL18576554 | 0.85 | MGLL (0.35) | SLC18A2CYP1A2CYP2D6HIF1AKMT2A | |
| SCHEMBL24901025 | 0.84 | SLC18A2 (0.34) | SLC18A2CYP1A2CYP2D6HIF1AKMT2A | |
| SCHEMBL21937220 | 0.83 | SLC18A2 (0.32) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL15318102 | 0.82 | SLC18A2 (0.33) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL26341933 | 0.81 | SLC18A2 (0.32) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL15933254 | 0.78 | SLC18A2 (0.31) | SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022261120-A1 | nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| WO-2014016317-A1 | SYNTHESIS OF DIVERSE GLYCOSYLPHOSPHATIDYLINOSITOL GLYCANS FROM TOXOPLASMA GONDII AND THEIR APPLICATION AS VACCINES AND DIAGNOSTICS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-30 | — | — | WO | disclosed |
| EP-2690438-A1 | Synthesis of diverse glycosylphosphatidylinositol glycans and glycolipids from toxoplasma gondii and their application as diagnostic markers and vaccines | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-29 | — | — | EP | disclosed |
| EP-2690104-A1 | Synthesis of diverse glycosylphosphatidylinositol glycans from toxoplasma gondii and their application as vaccines and diagnostics | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | SLC18A2 4069/4885CYP1A2 1281/4885CYP2D6 2079/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | SLC18A2 3529/4885CYP1A2 906/4885CYP2D6 2542/4885 |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | INMT, CARM1, KDM1B | SLC18A2 1655/4885CYP1A2 1947/4885CYP2D6 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.